Stopping permanently, by choice
You withdraw consent for further treatment. Legally and ethically this is always yours to do, whatever the medical recommendation.
Free second opinion on an existing chemotherapy plan · 1800 202 8726 · 9:30 AM–6 PM, Mon–Sat
When you have had enough
Yes — it is your decision, and it always has been. What changes is what stopping costs you, and that depends almost entirely on whether the treatment is meant to cure you or to keep you well. Here is the honest version of both.
One of our oncology nurses calls you back. No charge, no obligation.
Yes. You can stop chemotherapy at any point, and you do not need anyone's permission. As an adult you have the right to refuse or discontinue treatment, and treatment cannot be given without your consent — which you can withdraw after you have already started.
What is worth knowing before you do is that “stopping” covers six quite different situations, and that the consequences differ enormously depending on whether your treatment is meant to cure the cancer or to control it. Almost everything else on this page follows from that one distinction.
Be precise about this
People use one phrase for six situations, and the conversation goes wrong when patient and doctor mean different ones. Work out which of these you are actually asking about.
You withdraw consent for further treatment. Legally and ethically this is always yours to do, whatever the medical recommendation.
A deliberate pause of weeks or months to let your body recover, usually agreed with your team and with the intention of resuming.
The next cycle is postponed, most often because blood counts have not recovered. Reactive, common and not a judgement on you.
The same drugs at a lower dose, usually after repeated delays or because an organ is feeling the strain.
Recommended when the drugs are not controlling the cancer, or when further treatment is unlikely to help and is likely to harm.
Different drugs, or a different kind of treatment, because this one is not working well enough or is not tolerable.
The fork in the road
Ask your oncologist one question before anything else: is this treatment meant to cure me, or to keep me well for as long as possible? The answer puts you on one side of this page or the other.
Where chemotherapy is given to cure the cancer or to reduce the chance of it coming back, how much of the planned dose you actually receive appears to matter. In resected bowel cancer, patients who received more than 80 per cent of the planned dose intensity had materially better survival across all three drug components. In diffuse large B‑cell lymphoma, a systematic review found lower dose intensity associated with worse survival in seven of nine studies reporting it.
Two honest caveats. None of this is randomised — nobody has ethically randomised patients to finish or not finish curative chemotherapy — so it is a strong, consistent association rather than proof. And in patients over 80, the lymphoma review found survival was not consistently affected by reduced dose intensity. Age and fitness change the sum.
Where the cancer cannot be cured and treatment is given to control symptoms and extend good-quality time, the calculus genuinely differs. In the landmark randomised trial of early palliative care in metastatic lung cancer, patients who got palliative care alongside oncology had better quality of life, less than half the rate of depression (16 versus 38 per cent), less aggressive treatment at the end of life — and lived longer, a median 11.6 months against 8.9.
Guidelines go further. ASCO's Choosing Wisely advice is not to use cancer-directed therapy where performance status is poor, previous treatments have not helped and there is no strong evidence more will, with palliative and supportive care instead.
De-catastrophising
Being told your cycle is postponed is not the same as the treatment going wrong. Cancer Research UK: “It is important not to think of this as a setback.”
There is almost always an option between carrying on exactly as you are and stopping altogether. Tell us what is making treatment unbearable and a CION oncologist will review it with you — free, and without taking over your care.
An oncology nurse calls you back, usually the same working day.
There is usually a third option
Almost every reason for wanting to stop has an intermediate answer that most patients are never offered, because they stopped before they mentioned it. Open the one that is yours.
Usually fixable. ASCO recommends a four-drug combination for the most emetogenic regimens, and adding olanzapine roughly doubles the odds of no nausea and no vomiting in meta-analysis. Tell your team before the next cycle.
ASCO strongly recommends exercise during treatment, alongside cognitive behavioural therapy, mindfulness and tai chi. It explicitly does not recommend stimulants such as methylphenidate or modafinil for this.
Report it early. The guideline response is to delay, reduce or switch the offending drug, and duloxetine is the one drug ASCO says may be offered for painful neuropathy. It usually improves after treatment, but can be permanent in a small number of people.
Salt and bicarbonate rinses, benzydamine mouthwash, and for certain regimens sucking ice chips during the infusion — a specific guideline recommendation for bolus 5‑FU and high-dose melphalan.
Ask for the hospital's counselling team before you decide. Aarogyasri, CGHS, ECHS, cashless insurance and biosimilar substitution all change the arithmetic. See below.
Distance is a documented reason treatment gets abandoned in India. Ask whether cycles, blood tests or follow-up can happen at a centre closer to you — CION has 35+ across Telangana and Andhra Pradesh.
One in four people with cancer experiences depression, and it is treatable. In the early palliative care trial, proper support roughly halved the rate of depressive symptoms. This is a reason to ask for help, not a reason to stop.
Ask directly: what is the current status, how will we know, and what are the remaining options including trials? That is a conversation, not a reason to walk away quietly.
Alongside prescribed treatment is a different matter from instead of it. In curable cancers, people who used complementary medicine refused chemotherapy about ten times more often and had lower five-year survival — and the risk tracked with the refusal.
Call your team immediately if your temperature goes above 37.5°C or below 36°C, or reaches 38°C; if you have four or more loose stools in 24 hours; if you cannot keep fluids or tablets down for a day; if you are bleeding or bruising unusually; or if you have new breathlessness, chest pain, confusion or one-sided leg swelling. When white cells are low, a minor infection can become life-threatening within hours.
These are reasons to ring the 24-hour line, not reasons to abandon treatment. Stopping because of a complication that could have been treated is the one version of this decision that people most often regret. CION's helpline is 1800 202 8726.
If you do stop
Ten minutes well spent
Cure, risk reduction, shrinking before surgery, or control. Everything else depends on this answer and many patients have never been told it in plain words.
“Do I have to decide today, or is there room to think and get another opinion?” Often there is more room than it feels like.
Not in general — for you, for your cancer, at this point in the course. And ask what continuing would realistically buy you.
It changed the plan in roughly one case in three in one cancer centre's own data, often towards less intensive treatment. It is free at CION and you keep your own doctor.
The most fixable reason
Before deciding that money means stopping is the only option, have this conversation. It is the reason with the most available answers and the one patients raise last.
Indian data puts average annual out-of-pocket spend per cancer patient at about ₹3.31 lakh, with 80 per cent of outpatients facing catastrophic expenditure. In one regional centre's paediatric series, financial hardship was the single commonest reason treatment was abandoned.
Aarogyasri empanelment, CGHS, ECHS and EHS, and major cashless insurers. NABH and NABL accredited, ISO 9001:2015 certified. Ask what needs pre-authorisation before the cycle, not after it.
WHO puts biosimilars at roughly 60 per cent cheaper than the originator biologic. One Indian trastuzumab biosimilar launched at about 65 per cent below the brands then available, taking an 18-cycle course from around ₹10 lakh to under ₹4 lakh.
I would rather have the conversation than find out in six months that somebody stopped because of sickness we could have controlled in a single phone call.Dr. Naresh Gundu, Consultant Medical Oncologist, CION Cancer Clinics
Who reviews this page
Consultant Medical Oncologist, CION Cancer Clinics
MBBS, DNB, DM (Medical Oncology)
Dr. Gundu treats solid tumours with chemotherapy, targeted therapy and immunotherapy, and reviews CION's patient information on systemic treatment.
Female specialists practise in all three oncology disciplines. Ask the helpline if you would prefer to see a woman oncologist.
Leave a number. A CION oncologist will review your plan with you, at no charge, and tell you honestly what the options between carrying on and stopping are.
In patients' own words
Every CION patient story is a filmed interview, not a written quote. We do not publish testimonials we cannot show you on camera.
Where to come
One helpline serves every branch — there are no separate numbers to hunt for.
Day-care chemotherapy, consultations and blood work
Day-care chemotherapy, consultations and blood work
Day-care chemotherapy, consultations and blood work
Day-care chemotherapy, consultations and blood work
Day-care chemotherapy, consultations and blood work
Day-care chemotherapy, consultations and blood work
Day-care chemotherapy, consultations and blood work
Day-care chemotherapy, consultations and blood work
Day-care chemotherapy, consultations and blood work
Day-care chemotherapy, consultations and blood work
Head office: Road No 1, Plot No. 573/I, 1st Floor, Park View Building, Jubilee Hills, Hyderabad 500033. Helpline 1800 202 8726, open 24/7; clinics 9:30 AM–6 PM Monday to Saturday.
The questions patients actually ask
Yes. As an adult you can refuse or discontinue treatment at any point, and no treatment can be given without your permission. You can also change your mind again afterwards.
You can refuse part of a plan without refusing all of it — declining further chemotherapy while continuing pain control and supportive care is a normal, recognised choice.
No, and the difference matters. A planned break of weeks or months is meant to let your body recover, with the intention of resuming. Stopping altogether usually means shifting the goal of care towards comfort.
A dose delay is a third thing again — your team postponing the next cycle because your blood counts have not recovered. That is routine, not a failure.
No. In a study of 16,233 patients across six cancer types in routine practice, delays of a week or more happened in anywhere from 23 to 88 per cent of patients depending on the regimen. For many regimens a delay is closer to the norm than the exception.
Cancer Research UK puts it plainly: it is important not to think of this as a setback. Chemotherapy affects some people more than others and doses have to be adjusted for that.
It depends entirely on why you are being treated. Where the aim is cure, observational evidence in bowel cancer and in lymphoma consistently links receiving a lower proportion of the planned dose to worse survival. The breast cancer evidence points the same way but is more mixed, and one recent analysis suggests the reason for a dose reduction matters, not just its size.
Where the aim is control rather than cure, stopping has not been shown to shorten life — and in the landmark trial of early palliative care, patients who received less aggressive treatment at the end of life lived longer, not shorter.
Often, yes. Major cancer bodies treat restarting as a live option, and you can even leave hospice care to resume treatment if you change your mind.
Whether the same regimen is the right one to resume with depends on how the cancer behaved during the gap. That needs fresh scans and blood tests, and it is a question for your own oncologist rather than a general rule.
It is worth it. In one major cancer centre's own data, a second opinion changed the treatment plan in roughly one case in three — and for most of those patients the revised plan cost less, while about one in ten got a better survival estimate.
It does not mean leaving your doctor. As that centre puts it, good doctors welcome a second opinion and often recommend one. A second opinion on an existing plan is free at CION.
Alongside prescribed treatment is a different question from instead of it. A large US study of non-metastatic breast, prostate, lung and bowel cancer found that people using complementary medicine refused chemotherapy about ten times more often, and had lower five-year survival — 82.2 per cent against 86.6 per cent.
The important finding was that the excess risk tracked with refusing effective treatment, not with using complementary therapy itself. Tell your team what you are taking rather than choosing between them.
Next step
Bring your chemotherapy chart and your scans. We will tell you what the aim of your treatment is, what stopping would mean in your case, and what lies between the two. You keep your current doctor.
Tell us what you need and an oncology nurse will call you.
General information, not a prescription. This page explains what is generally true for people having chemotherapy. It is not advice about your own treatment, and nothing on it should be used to start, stop or change a medicine. Your own oncology team knows your diagnosis, your drugs, your blood results and your other conditions — we do not. If anything here worries you, or anything about your treatment feels wrong, call your team on 1800 202 8726. The helpline is answered 24 hours a day.